The gemaker team worked closely with the Australian Precision Medicine Enterprise (APME) partners to prepare a successful application for $23M funding from the Australian Government’s Modern Manufacturing Initiative (MMI) to establish a new theranostics capability in Australia.
Theranostics is precision medicine at the molecular level, using a radioactive imaging diagnostic with a therapeutic radioactive drug, to identify and treat cancer tumours and other disease. Translating this technology into economic and health benefits for Australians is the purpose of the APME.
As part of this project, gemaker assisted with improving their investment case, project managed the grant application, and developed the overall project plan for inclusion in the evidence-based submission.
This included the following roles:
- undertaking local and international market research on new radiopharmaceutical opportunities in Australia
- conducting stakeholder interviews and gap analysis
- preparation of market summary report
- development of detailed budget and review of cashflow modelling
- preparation of governance framework and risk analysis matrix
- review of IP management plan
- drafting of grant submission and supporting materials
MMI funding will enable construction of nationally-significant infrastructure including two large cyclotrons. The APME will be a centre of excellence for theranostics R&D, clinical trials and commercial manufacturing. The aim is to build a globally competitive precision medicine industry.